-
Bynum Troelsen posted an update 6 months, 1 week ago
ce of clinical symptoms after discharge as well as CT findings. It is recommended to detect feces or other specimens in discharged patients, and to strengthen the regular monitoring and follow-up of discharged patients.
Some patients with COVID-19 in Wuhan Mobile Cabin Hospital who were re-positive with 2019-nCoV nucleic acid after discharge did not cause further transmission. Moreover, the patients with re-positive nucleic acid results were not significantly correlated with their length of hospital stay and the presence of clinical symptoms after discharge as well as CT findings. It is recommended to detect feces or other specimens in discharged patients, and to strengthen the regular monitoring and follow-up of discharged patients.
To evaluate the effectiveness and safety of convalescent plasma therapy in patients with severe and critical coronavirus disease 2019 (COVID-19).
Plasma of 200-400 mL was collected from convalescent patients 2 weeks after being discharged from the hospital. After viral nucleic acid testing and antibody testing, the plasma was infused into 16 severe or critical COVID-19 patients. Time for viral nucleic acid amplification (NAA) test turning negative, total volume of plasma transfusion, average antibody concentration, and total antibody amount were recorded. White blood cell (WBC) counts, lymphocyte (LYM) counts, neutrophil (NEU) counts, alanine aminotransferase (ALT), aspartate aminotransferase (AST), C-reactive protein (CRP), procalcitonin (PCT), lactate dehydrogenase (LDH), creatine kinase (CK), creatine kinase isoenzyme (CK-MB), hypersensitive cardiac troponin T (hs-cTnT), and lactic acid (Lac) levels were measured and the rate of change was calculated at the baseline (d0) before plasma transfusion, and asma of high-titer antibody and early application to severe and critical patients are expected to improve the efficacy of convalescent plasma.
Viral NAA test of most patients with COVID-19 who received convalescent plasma transfusion turned negative from day 2 to day 8 after transfusion, and the turning time of severe patients was shorter than that of critical patients. Convalescent plasma therapy can reduce the patients’ CRP level, and no adverse events were found during the treatment. The antibody concentration in the convalescent plasma may be one of the factors that affect the time for the nucleic acid turning negative after transfusion. Detection and screening convalescent plasma of high-titer antibody and early application to severe and critical patients are expected to improve the efficacy of convalescent plasma.With the development of society and economy, people’s requirements for emergency rescue technology and emergency services are gradually increasing. Building and improving the emergency of critical care system is an important issue currently facing. Controlling medical injuries is the goal of medical development. At present, people’s requirements for first aid measures have shown a trend from invasive to minimally invasive even non-invasive. It is a new requirement for emergency medicine in the new era to establish a minimally invasive emergency system and apply the minimally invasive technology in the first-aid and critical care area, to help the patients with acute and critical illness overcome difficulties, improve outcome, and enhance the quality of life.This expert consensus uses clinical research evidence to explain the mechanism, monitoring and evaluation of sepsis-induced immunosuppression, and treatment with immune stimulation from two aspects innate immunity and acquired immunity, aiming to help clinicians better understand sepsis-induced immune depression and its clinical significance. Clinical data suggest that the immune dysfunction is critically involved in the occurrence and development of sepsis. Quantitative detection of monocyte human leukocyte antigen DR and lymphocyte count can be used as important indicators to reflect the innate immune and acquired immune dysfunction in patients with sepsis. Immunomodulation therapy includes medication to improve innate immunity and acquired immunity, and immune stimulation combined with anti-inflammatory response.
Neuregulin 4 (Nrg4) is a novel adipocytokine that has been proposed to play a role in modulating energy metabolism and pathogeneses of atherosclerosis. However, no published research is available about the mechanisms underlying the anti-atherosclerotic effect of Nrg4. buy Estradiol Benzoate Regarding the close link between adipocytokines and the immune system, we wonder whether there is a relation between Nrg4 and athero-protective cytokines. The aim of this study was to investigate the relationship between serum Nrg4 levels and type 2 cytokines in Iranian patients with coronary artery disease (CAD).
In this case-control study, 125 CAD patients were compared to 55 healthy controls. The serum concentrations of Nrg4, IL-5, IL-9, and IL-13 were measured using ELISA. The associations of circulating Nrg4 and IL-5, IL-9, IL-13 were assessed using linear regression analyses.
Serum concentration of IL-9 was significantly higher in patients compared to the healthy controls (317.9±139 versus 228.3±99.1, P= ˂0.0001). IL-13 and Nrg4 were significantly lower in patients compared to the healthy controls (4.3±3.7 versus 6.1±3.9, P=0.01 and 0.5 versus 1.3, P=0.001 respectively). Multiple linear regression analyses revealed that IL-9 was negatively correlated with Nrg4 (β= -0.3, P=0.009).
Our study, for the first time, provides the clinical evidence revealing that circulating Nrg4 concentrations are inversely correlated with IL-9 in Iranian patients with CAD, suggesting that the protective role of Nrg4 on atherosclerosis may be, in part, mediated by the proatherogenic cytokine, IL-9.
Our study, for the first time, provides the clinical evidence revealing that circulating Nrg4 concentrations are inversely correlated with IL-9 in Iranian patients with CAD, suggesting that the protective role of Nrg4 on atherosclerosis may be, in part, mediated by the proatherogenic cytokine, IL-9.Arachidonic acids and its metabolites modulate plenty of ligand-gated, voltage-dependent ion channels, and metabolically regulated potassium channels including ATP-sensitive potassium channels (KATP). KATP channels are hetero-multimeric complexes of sulfonylureas receptors (SUR1, SUR2A or SUR2B) and the pore-forming subunits (Kir6.1 and Kir6.2) likewise expressed in the pre-post synapsis of neurons and inflammatory cells, thereby affecting their proliferation and activity. KATP channels are involved in amyloid-β (Aβ)-induced pathology, therefore emerging as therapeutic targets against Alzheimer’s and related diseases. The modulation of these channels can represent an innovative strategy for the treatment of neurodegenerative disorders; nevertheless, the currently available drugs are not selective for brain KATP channels and show contrasting effects. This phenomenon can be a consequence of the multiple physiological roles of the different varieties of KATP channels. Openings of cardiac and muscular KATP channel subunits, are protective against caspase-dependent atrophy in these tissues and some neurodegenerative disorders, whereas in some neuroinflammatory diseases, benefits can be obtained through the inhibition of neuronal KATP channel subunits.